These include mono agonists, glucagonlike peptide-1 receptor agonists (GLP-1 agonists), and dual agonists that combine a glucose-dependent insulinotropic polypeptide (GIP) with a GLP-1 agonist (GIP/GLP-1), which have demonstrated a 15% and greater weight loss in people with obesity and/or type 2 diabetes, says Richard E
Want the gentle lane explained? Read our guide to microdosing semaglutide, or compare starting doses side by side in the GLP-1 microdosing dose chart
Hoping it picks back up soon cause this is getting expensive Michelle A., 36, Halifax NS Neither concern is valid
The current state of access to weight loss drugs isnt serving everyone who needs them, said Andrew Dudum, CEO and co-founder of Hims & Hers
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al